FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059383458> ?p ?o ?g. }

• W2059383458 endingPage "e11241" @default.
• W2059383458 startingPage "e11241" @default.
• W2059383458 abstract "Background The endothelin B receptor (ETBR) promotes tumorigenesis and melanoma progression through activation by endothelin (ET)-1, thus representing a promising therapeutic target. The stability of hypoxia-inducible factor (HIF)-1α is essential for melanomagenesis and progression, and is controlled by site-specific hydroxylation carried out by HIF-prolyl hydroxylase domain (PHD) and subsequent proteosomal degradation. Principal Findings Here we found that in melanoma cells ET-1, ET-2, and ET-3 through ETBR, enhance the expression and activity of HIF-1α and HIF-2α that in turn regulate the expression of vascular endothelial growth factor (VEGF) in response to ETs or hypoxia. Under normoxic conditions, ET-1 controls HIF-α stability by inhibiting its degradation, as determined by impaired degradation of a reporter gene containing the HIF-1α oxygen-dependent degradation domain encompassing the PHD-targeted prolines. In particular, ETs through ETBR markedly decrease PHD2 mRNA and protein levels and promoter activity. In addition, activation of phosphatidylinositol 3-kinase (PI3K)-dependent integrin linked kinase (ILK)-AKT-mammalian target of rapamycin (mTOR) pathway is required for ETBR-mediated PHD2 inhibition, HIF-1α, HIF-2α, and VEGF expression. At functional level, PHD2 knockdown does not further increase ETs-induced in vitro tube formation of endothelial cells and melanoma cell invasiveness, demonstrating that these processes are regulated in a PHD2-dependent manner. In human primary and metastatic melanoma tissues as well as in cell lines, that express high levels of HIF-1α, ETBR expression is associated with low PHD2 levels. In melanoma xenografts, ETBR blockade by ETBR antagonist results in a concomitant reduction of tumor growth, angiogenesis, HIF-1α, and HIF-2α expression, and an increase in PHD2 levels. Conclusions In this study we identified the underlying mechanism by which ET-1, through the regulation of PHD2, controls HIF-1α stability and thereby regulates angiogenesis and melanoma cell invasion. These results further indicate that targeting ETBR may represent a potential therapeutic treatment of melanoma by impairing HIF-1α stability." @default.
• W2059383458 created "2016-06-24" @default.
• W2059383458 creator A5017244417 @default.
• W2059383458 creator A5019259641 @default.
• W2059383458 creator A5039788126 @default.
• W2059383458 creator A5049435911 @default.
• W2059383458 creator A5054472524 @default.
• W2059383458 creator A5070190573 @default.
• W2059383458 creator A5090987336 @default.
• W2059383458 date "2010-06-21" @default.
• W2059383458 modified "2023-10-16" @default.
• W2059383458 title "Endothelin-1 Inhibits Prolyl Hydroxylase Domain 2 to Activate Hypoxia-Inducible Factor-1α in Melanoma Cells" @default.
• W2059383458 cites W1511251378 @default.
• W2059383458 cites W1651215666 @default.
• W2059383458 cites W1915693503 @default.
• W2059383458 cites W1974019125 @default.
• W2059383458 cites W1977461220 @default.
• W2059383458 cites W1980138733 @default.
• W2059383458 cites W1982391915 @default.
• W2059383458 cites W1986014993 @default.
• W2059383458 cites W1986827117 @default.
• W2059383458 cites W1988377666 @default.
• W2059383458 cites W1990607537 @default.
• W2059383458 cites W1990653694 @default.
• W2059383458 cites W1998837017 @default.
• W2059383458 cites W2004646359 @default.
• W2059383458 cites W2007868595 @default.
• W2059383458 cites W2008182675 @default.
• W2059383458 cites W2009936217 @default.
• W2059383458 cites W2011810742 @default.
• W2059383458 cites W2017575850 @default.
• W2059383458 cites W2023884228 @default.
• W2059383458 cites W2024774077 @default.
• W2059383458 cites W2030319693 @default.
• W2059383458 cites W2036083286 @default.
• W2059383458 cites W2039627657 @default.
• W2059383458 cites W2040031153 @default.
• W2059383458 cites W2042216712 @default.
• W2059383458 cites W2043649214 @default.
• W2059383458 cites W2046990824 @default.
• W2059383458 cites W2064520370 @default.
• W2059383458 cites W2066199622 @default.
• W2059383458 cites W2069870955 @default.
• W2059383458 cites W2075880922 @default.
• W2059383458 cites W2082483448 @default.
• W2059383458 cites W2096209217 @default.
• W2059383458 cites W2098430250 @default.
• W2059383458 cites W2100132196 @default.
• W2059383458 cites W2101084498 @default.
• W2059383458 cites W2118484233 @default.
• W2059383458 cites W2120483851 @default.
• W2059383458 cites W2140346107 @default.
• W2059383458 cites W2145023430 @default.
• W2059383458 cites W2148946562 @default.
• W2059383458 cites W2154245736 @default.
• W2059383458 cites W2154327042 @default.
• W2059383458 cites W2157276028 @default.
• W2059383458 cites W2160176769 @default.
• W2059383458 cites W2166932492 @default.
• W2059383458 cites W2168128490 @default.
• W2059383458 cites W2169517188 @default.
• W2059383458 cites W4244089942 @default.
• W2059383458 doi "https://doi.org/10.1371/journal.pone.0011241" @default.
• W2059383458 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2888584" @default.
• W2059383458 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20574527" @default.
• W2059383458 hasPublicationYear "2010" @default.
• W2059383458 type Work @default.
• W2059383458 sameAs 2059383458 @default.
• W2059383458 citedByCount "46" @default.
• W2059383458 countsByYear W20593834582012 @default.
• W2059383458 countsByYear W20593834582013 @default.
• W2059383458 countsByYear W20593834582014 @default.
• W2059383458 countsByYear W20593834582015 @default.
• W2059383458 countsByYear W20593834582016 @default.
• W2059383458 countsByYear W20593834582017 @default.
• W2059383458 countsByYear W20593834582018 @default.
• W2059383458 countsByYear W20593834582020 @default.
• W2059383458 countsByYear W20593834582021 @default.
• W2059383458 countsByYear W20593834582022 @default.
• W2059383458 countsByYear W20593834582023 @default.
• W2059383458 crossrefType "journal-article" @default.
• W2059383458 hasAuthorship W2059383458A5017244417 @default.
• W2059383458 hasAuthorship W2059383458A5019259641 @default.
• W2059383458 hasAuthorship W2059383458A5039788126 @default.
• W2059383458 hasAuthorship W2059383458A5049435911 @default.
• W2059383458 hasAuthorship W2059383458A5054472524 @default.
• W2059383458 hasAuthorship W2059383458A5070190573 @default.
• W2059383458 hasAuthorship W2059383458A5090987336 @default.
• W2059383458 hasBestOaLocation W20593834581 @default.
• W2059383458 hasConcept C104317684 @default.
• W2059383458 hasConcept C149601957 @default.
• W2059383458 hasConcept C153911025 @default.
• W2059383458 hasConcept C160450060 @default.
• W2059383458 hasConcept C167734588 @default.
• W2059383458 hasConcept C170493617 @default.
• W2059383458 hasConcept C173396325 @default.
• W2059383458 hasConcept C2777025900 @default.
• W2059383458 hasConcept C502942594 @default.

• next